NEW YORK (GenomeWeb) – Tempus announced today that it has partnered with the University of California Davis Comprehensive Cancer Center to develop personalized medicine regimens for cancer patients.
Under the alliance, Tempus will perform next-generation sequencing on a group of patients at the cancer center, initially focusing on individuals with hematological malignancies and pancreatic cancer. The firm will use machine learning and advanced bioinformatics to analyze the resulting data to identify molecular patterns that may help guide treatment decisions for patients unlikely to respond to conventional therapies or for whom such therapies don't exist.
"Discovery is happening at a rapid pace and will continue to accelerate with access to data-driven tools designed to support work in the clinic," Primo Lara, interim director of the UC Davis Comprehensive Cancer Center, said in a statement. "Working with Tempus is consistent with our commitment to providing our physicians with the tools and resources they need to best treat their patients."
In June, Tempus began collaborating with University of Chicago Medicine to study clinical and molecular data from pancreatic cancer patients in order to improve the prediction of treatment responses. Earlier that month, the company struck a similar deal with the University of Michigan focused on breast cancer. And in March, Tempus partnered with University of Chicago Medicine to perform molecular sequencing on about 1,000 breast cancer patients.